Mein Warenkorb

B7-CD28 Family——PD-1/PD-L1/PD-L2 Pathway

The PD-1/PD-L1/PD-L2 pathway is a key "brake" mechanism in the immune system. In the field of cancer therapy, inhibitors targeting this pathway have become revolutionary treatments. Through their interactions, this pathway inhibits the activation, proliferation, and effector functions of T cells, thereby maintaining self-immunotolerance under physiological conditions. However, in the tumor microenvironment, it is exploited by tumors to achieve immune escape.
As a "cornerstone track" in cancer immunotherapy, the PD-(L)1 field has undergone over a decade of development since the first drug was approved, yet it remains highly active. To improve efficacy and overcome resistance, combination therapies (such as in combination with chemotherapy and anti-angiogenic drugs) and novel drugs like bispecific antibodies have become important R&D directions.

>>>Immune Checkpoint Bispecific Antibody Targets

The PD-1/PD-L1 Axis and Co-signaling Networks: Orchestrating T Cell Responses in Cancer and Autoimmunity

The PD-1/PD-L1 Axis and Co-signaling Networks: Orchestrating T Cell Responses in Cancer and Autoimmunity
Resource:https://www.globecancer.com/azzx/show.php?itemid=15812

>> Scroll to view

Drug Strategy Strategy Type Representative Drugs / Regimens Core Mechanism / Objective
PD-L1-targeting ADC
ADC
1. PD-L1 ADC: Henlius HLX43
2. PD-L1/αvβ6 integrin BsADC: Alphamab JSKN022
1. Target PD-L1 and achieve targeted killing through the cytotoxic payload of ADC
2. Dual targeting of PD-L1 and αvβ6 integrin to enhance tumor targeting and killing efficacy
PD-1 Plus: BsAb
Immune Escape Inhibition + Anti-angiogenesis
PD-1/VEGF BsAb: Akeso Ivonescimab (AK112)
Simultaneously block PD-1-mediated immune escape signals, inhibit VEGF-mediated tumor angiogenesis, improve the tumor microenvironment, and enhance immunotherapeutic efficacy.
Immune Escape Inhibition + Immune Agonism
1. PD-1/IL-2 BsAb: InnoCare IBI363
2. PD-L1/4-1BB BsAb: ImmuneOnco LBL-024
While blocking immune escape, activate immune effector cells such as T cells through the IL-2/4-1BB pathway to overcome immunotherapy resistance.
Multiple Immune Escape Inhibition
1. PD-1/TIGITBsAb: AstraZeneca Rivegostomig
2. PD-1/CTLA-4BsAb: Akeso Cadonilimab
Simultaneously block multiple immune checkpoint pathways including PD-1, TIGIT, and CTLA-4 to strengthen the inhibition of immune escape.
Combination of PD-1/PD-L1 Inhibitor and ADC
Combination Therapy
PD-1 Inhibitor Keytruda + Nectin-4 ADC Padcev
Leverage the targeted killing effect of ADC and the immune activation function of PD-1/PD-L1 inhibitor to achieve synergistic antitumor effect and improve treatment response.
To meet your R&D needs for drugs targeting the PD-(L)1/PD-L2 pathway, ACROBiosystems has specifically developed a series of products covering the entire R&D pipeline. These include highly active PD-1/PD-L1/PD-L2 target proteins, PD-1/PD-L1 functional cell lines, and inhibitor screening kits, catering to the entire process from basic mechanism research to preclinical drug evaluation and production quality control.
Furthermore, addressing potential unconventional needs in R&D, we also offer customized services: such as specific species/mutant protein customization, exclusive functional cell model construction, and experimental protocol optimization guidance. This aims to accelerate your R&D process for drugs related to the PD-1/PD-L1/PD-L2 pathway, enhancing drug screening efficiency and clinical translation success rates.

Product Features

Protein
High purity verified by MALS/HPLC.
Multiple species, tags, labels.
High bioactivity verified by ELISA/SPR/FACS.
Stringent QC ensures high batch-to-batch consistency.
Functional Cell Lines
Developed based on mature cell construction platforms, strictly screened and validated.
Stable passage >20 generations, ensuring reliable experimental results.
Original cell lines obtained with legal commercial licenses, global commercial authorization support available.
Inhibitor Screening Kits
Two technical routes: Competitive ELISA and TR-FRET
TR-FRET-based: Wash-free; High-throughput (supports 500 tests); Comprehensive verification data
Competitive ELISA-based: Accurate and reliable; High reproducibility; 96T & fast universal; Minimal matrix interference
Pharmacokinetic (PK) Assay Kits
Low background
Universal and fast
High batch-to-batch consistency
High stability
Diversified product line

Product List

Protein
Cell Line
Inhibitor Screening ELISA
PK ADA ELISA
Cat. No.MoleculeProduct DescriptionVorbestellen/Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen
Bestellen

Validation Data

Electrophoresis (SDS-PAGE)
Electrophoresis (SDS-PAGE)

Human PD-L1, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 98% (With Star Ribbon Pre-stained Protein Marker).

Protein High Purity Verified by SEC-MALS
Protein High Purity Verified by SEC-MALS

The purity of Human PD-L1, His Tag (Cat. No. PD1-H5229) is more than 90% and the molecular weight of this protein is around 30-50kDa verified by SEC-MALS.

Request Report
High Binding Activity of PD-1 to PD-L2 Verified by ELISA
High Binding Activity of PD-1 to PD-L2 Verified by ELISA

Immobilized Human PD-1, His Tag (Cat. No. PD1-H5221) at 2 μg/mL (100 μL/well) can bind Human PD-L2, Mouse IgG1 Fc Tag (Cat. No. PD2-H52A5) with a linear range of 10-156 ng/mL (Routinely tested).

Request Protocol

High Binding Affinity of PD-1 to PD-L1 Verified by SPR
High Binding Affinity of PD-1 to PD-L1 Verified by SPR

Human PD-1, Fc Tag (Cat. No. PD1-H5257) captured on CM5 chip via anti-human IgG Fc antibody, can bind Human PD-L1, His Tag (Cat. No. PD1-H5229) with an affinity constant of 3.6 μM as determined in a SPR assay (Biacore T200) (Routinely tested).

Request Protocol

High Binding Affinity of PD-1 to PD-L1 Verified by BLI
High Binding Affinity of PD-1 to PD-L1 Verified by BLI

Loaded Human PD-1, Fc Tag, low endotoxin (Cat. No. PD1-H5257) on Protein A Biosensor, can bind Human PD-L1, His Tag (Cat. No. PD1-H5229) with an affinity constant of 5.3 μM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).

Request Protocol

High Binding Affinity of PD-1 to PD-L1 Verified by Cellular Assay
High Binding Affinity of PD-1 to PD-L1 Verified by Cellular Assay

Immobilized cell surface PD-1 (5x104 of cells per well) can bind Human PD-L1, Fc Tag (Cat. No. PD1-H5258) with an EC50 of 0.029 μg/mL (Routinely tested).

Request Protocol

High Binding Activity of PD-L1 to PD-L1 Antibody Verified by ELISA
High Binding Activity of PD-L1 to PD-L1 Antibody Verified by ELISA

Immobilized Biotinylated Human PD-L1, Avitag,His Tag (Cat. No. PD1-H82E5) at 1 μg/mL (100 μL/well) on Streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind Anti-PD-L1 MAb, Human IgG1 with a linear range of 0.2-3 ng/mL (Routinely tested).

Request Protocol

High Binding Affinity of PD-L1 to PD-L1 Antibody Verified by SPR
High Binding Affinity of PD-L1 to PD-L1 Antibody Verified by SPR

Anti-Human PD-L1 Mab (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human PD-L1, His Tag (Cat. No. PD1-H5229) with an affinity constant of 0.286 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Request Protocol

Binding Activity to BSAb Verified by ELISA
Binding Activity to BSAb Verified by ELISA

Immobilized Human PD-1, His Tag (Cat. No. PD1-H5221) at 5 μg/mL, add increasing concentrations of Cadonilimab (PD-1 x CTLA-4 bispecific antibody) and then add Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) at 0.2 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) with sensitivity of 2.99 ng/mL (Routinely tested).

Request Protocol

Binding Activity to BSAb Verified by ELISA
Binding Activity to BSAb Verified by ELISA

Immobilized Human VEGF165, His Tag (Cat. No. VE5-H5248) at 2 μg/mL, add increasing concentrations of Ivonescimab and then add Biotinylated Human PD-1 Protein, Avitag,His Tag (Cat. No. PD1-H82E4) at 2 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) with sensitivity of 2.17 ng/mL (Routinely tested).

Request Protocol
The binding activity between PD-1 and PD-L1-overexpressing cell lines was verified by FACS.
The binding activity between PD-1 and PD-L1-overexpressing cell lines was verified by FACS.

Flow Cytometry assay shows that Human PD-1 Protein, Fc Tag (Cat. No. PD1-H5257) can bind to 293 cell overexpressing human PD-L1. The concentration of PD-1 used is 1 μg/mL (Routinely tested).

Request Protocol

The competitive inhibitory effect of PD-L1 antibodies on the binding of human PD-1/PD-L1 was verified by FACS.
The competitive inhibitory effect of PD-L1 antibodies on the binding of human PD-1/PD-L1 was verified by FACS.

FACS analysis shows that the binding of Human PD-L1, Fc Tag (Cat. No. PD1-H5258) to 293 overexpressing PD-1 was inhibited by increasing concentration of neutralizing Anti-PD-L1 antibody. The concentration of PD-L1 used is 10 μg/mL. The IC50 is 12.92 μg/mL (Routinely tested).

Request Protocol

Screening of PD1/PD-L1 inhibitors using the Human PD-1/PD-L1 Inhibitor Screening Kit (TR-FRET)
Screening of PD1/PD-L1 inhibitors using the Human PD-1/PD-L1 Inhibitor Screening Kit (TR-FRET)

The Human PD-1 / PD-L1 Inhibitor Screening Kit (TR-FRET) (Cat. No. FRT-P019) is suitable for the detection of PD1/PD-L1 inhibitors. It shows that both Atezolizumab, Nofazinlimab and Pembrolizumab exhibit good inhibitory activity in this TR-FRET competition assay.

Request Protocol

Detection of the inhibitory effect of anti-PD-L1 neutralizing antibodies on PD-L1: PD-1 binding using the PD-L1: PD-1 [Biotinylated] Inhibitor Screening Kit
Detection of the inhibitory effect of anti-PD-L1 neutralizing antibodies on PD-L1: PD-1 binding using the PD-L1: PD-1 [Biotinylated] Inhibitor Screening Kit

Serial dilutions of Anti-PD-L1 Neutralizing antibody (Cat. No. EP133) (1:1 serial dilution, from 2 μg/mL to 0.015625μg/mL) was added into PD-L1: Biotinylated PD-1 binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).

Request Protocol

Clinical Drug Information Table

Englischer NameForschungscodeForschungsphaseFirmaIndikationKlinische Studie
IO-120IO-120Io Biotech Aps
Details
IMGS-001IMGS-001Phase 1 ClinicalThe University Of Texas MD Anderson Cancer CenterSolid tumours; Neoplasms; Triple Negative Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms
Details
IO-120/ IO-103 (IO Biotech)IO-120/IO-103; IO-120+IO-103Phase 2 ClinicalIo Biotech IncLeukemia, Lymphocytic, Chronic, B-Cell
Details
89Zr-KN035(Wuxi No. 4 People's Hospital)ClinicalWuxi No. 4 PeopleSolid tumours
Details
CTB-1CTB-1ClinicalGTS Biotech LLCNeoplasms
Details
18F-BMS-986192BMS-986192-[18F]ClinicalBristol-Myers Squibb CompanyNeoplasms
Details
Durvalumab/Selumetinib sulfatePhase 1 ClinicalAstrazeneca PlcNeoplasms
Details
Recombinant anti-PD-L1 human monoclonal antibody (Jiansu huaiyu)Phase 1 ClinicalJiangsu Huaiyu Pharmaceutical Co LtdSolid tumours
Details
GarivulimabBGB-A333Phase 1 ClinicalBeOne Medicines LtdSolid tumours; Neoplasms
Details
BJ-005BJ-005Phase 1 ClinicalBoji Biomedical Technology (Hangzhou) Co LtdSolid tumours; Lymphoma
Details
SG12473SG12473; SG-12473Phase 1 ClinicalHangzhou Sumgen Biotechnology Co LtdHematologic Neoplasms; Solid tumours; Neoplasms
Details
IBI-323(Innovent Biologics)IBI-323Phase 1 ClinicalInnovent Biologics(Suzhou) Co LtdSolid tumours; Neoplasms
Details
GNC-039GNC-039Phase 1 ClinicalSichuan Baili Pharmaceutical Co LtdSolid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis
Details
SKB-337SKB337; A-337; SKB-337Phase 1 ClinicalSichuan Kelun-Biotech Biopharmaceutical Co LtdSolid tumours
Details
IMM2505IMM2505; IMM-2505Phase 1 ClinicalSunHo (China) BioPharmaceutical Co Ltd, ImmuneOnco Biopharmaceuticals (Shanghai) Co LtdSolid tumours
Details
QLS31901QLS-31901; QLS31901Phase 1 ClinicalQilu Pharmaceutical Co LtdNeoplasms
Details
Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University)Phase 1 ClinicalSichuan UniversityPeritoneal Neoplasms; Pleural Effusion, Malignant
Details
CCX-559CCX-559Phase 1 ClinicalChemocentryx IncSolid tumours; Neoplasms
Details
RagistomigABL-503; TJ-L14B/ABL503; ABL503; TJ-L14BPhase 1 ClinicalI-Mab Biopharma Co LtdSolid tumours
Details
GS-19GT-90008; GS-19; GS-19-PLB-1CPhase 1 ClinicalGensun Biopharma IncSolid tumours
Details
TST-005TST-005; TST005Phase 1 ClinicalMabspace Biomedicine (Suzhou) Co LtdSolid tumours; Neoplasms; Papillomavirus Infections
Details
BR-102BR102Phase 1 ClinicalBioRay Pharmaceutical Co LtdSolid tumours; Neoplasms
Details
AN-4005AN-4005Phase 1 ClinicalHangzhou Adlai Nortye Biopharma Co LtdSolid tumours; Neoplasms; Lymphoma
Details
PF-07257876Phase 1 ClinicalPfizer IncOvarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung
Details
TT-00420/AtezolizumabPhase 1 ClinicalTransThera Sciences (Nanjing) IncGastrointestinal Neoplasms
Details
CA-170CA-170; AUPM-170Phase 1 ClinicalAurigeneSolid tumours
Details
IMM-2520IMM-2520Phase 1 ClinicalImmuneOnco Biopharmaceuticals (Shanghai) Co LtdSolid tumours; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
FS222 mAb² (F-star Therapeutics)FS-222Phase 1 ClinicalF-star Beta LtdSolid tumours; Neoplasms; Neoplasm Metastasis
Details
Recombinant oncolytic type II herpes simplex virus (Binhui Biopharmaceutical)BS-006; oHSV2-BiTEs; oHSV2CD3-PD-L1Phase 1 ClinicalWuhan Binhui Biotechnology Co LtdSolid tumours; Neoplasms; Melanoma; Uterine Cervical Neoplasms
Details
CN-202CN-202Phase 1 ClinicalCuron Biopharmaceutical LtdSolid tumours; Hematologic Neoplasms
Details
SHS-006(Nanjing Sanhome Pharmaceutical)SHS-006; SH-006; SH006Phase 1 ClinicalNanjing Sanhome Pharmaceutical Co Ltd Solid tumours
Details
SHS-009SHS-009; SH009; SH-009Phase 1 ClinicalNanjing Sanhome Pharmaceutical Co Ltd Neoplasms
Details
Gallium [68Ga] Natan recombinant PD-L1 single domain antibodySNA-002; 68Ga-NOTA-SNA002Phase 1 ClinicalSmartnuclide BiopharmaSolid tumours; Neoplasms; Contrast agents
Details
706-3SBioSSGJ-706; 706 anti -PD1/PD -L1 BsAb; 706 anti-PD1/PD-L1 Bispecific antibodyPhase 1 Clinical3sbio IncSolid tumours; Composite Lymphoma; Neoplasms; Lymphoma
Details
CHECKvaccCF33-hNIS-antiPDL1Phase 1 ClinicalImugene Ltd, City Of Hope National Medical CenterTriple Negative Breast Neoplasms; Breast Neoplasms; Metastatic breast cancer
Details
SG-1408SG-1408; SG1408Phase 1 ClinicalHangzhou Sumgen Biotechnology Co LtdSolid tumours
Details
CS-23546CS-23546; CS23546Phase 1 ClinicalShenzhen Chipscreen Biosciences Co LtdNeoplasms; Immune System Diseases
Details
BPI-371153BPI-371153Phase 1 ClinicalBetta Pharmaceuticals Co LtdSolid tumours; Lymphoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular
Details
DR-30206DR-30206Phase 1 ClinicalZhejiang Doer Biologics CorpSolid tumours
Details
ASC-61ASC-61Phase 1 ClinicalAscletis Pharma IncSolid tumours; Neoplasms
Details
SGN-PDL1VSGN-PDL1V; PF-08046054Phase 1 ClinicalSeagen IncOvarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma
Details
QL-415QL-415Phase 1 ClinicalQlsf Biotherapeutics IncNeoplasms
Details
HS-10386HS-10386Phase 1 ClinicalJiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co LtdSolid tumours
Details
HBM-9027HBM-9027; HBM9027Phase 1 ClinicalHarbour BiomedSolid tumours; Neoplasms
Details
Ori-Bs-001Ori-Bs-001Phase 1 ClinicalOriCell Therapeutics Co LtdSolid tumours
Details
Dual-targeting VEGFR1 and PD-L1 CAR-T cells Therapy (Sichuan University)Phase 1 ClinicalSichuan UniversitySerositis; Ascites
Details
HK-010HK-010; HK010Phase 1 ClinicalAnhui Anke Biotechnology (Group) Co Ltd, Hefei Hankemab Biotechnology Co LtdNeoplasms
Details
RAD-203RAD-203Phase 1 ClinicalRadiopharm Theranostics LtdCarcinoma, Non-Small-Cell Lung
Details
177Lu-RAD204RAD-204; 177Lu-RAD204; 177Lu-anti-PD-L1 sdAbPhase 1 ClinicalRadiopharm Theranostics LtdSkin Melanoma; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
AUR-106AUR-106Phase 1 ClinicalAurigene Discovery Technologies LtdKidney Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
Recombinant anti-PD-L1/TGF-β bifunctional fusion proteinPhase 1 ClinicalHualan Genetic Engineering (Henan) Co LtdSolid tumours
Details
B-901B-901; B901Phase 1 ClinicalFutureGen Biopharm (Beijing) Co LtdSolid tumours
Details
KM602KM602; KM-602; XZP-KM602Phase 1 ClinicalXuanzhu (Shijiazhuang) Biotechnology Co LtdSolid tumours
Details
SPX-303SPX-303Phase 1 ClinicalSparX Biopharmaceutical CorpSolid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck
Details
ND-021ND-021; NM21-1480; CS-2006; CS2006Phase 1 ClinicalNumab Therapeutics Ag, Cstone PharmaceuticalsSolid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung
Details
BAT-7205BAT7205; BAT-7205Phase 1 ClinicalBio-Thera Solutions LtdSolid tumours; Neoplasm Metastasis
Details
YL-222YL222; YL-222Phase 1 ClinicalMediLink Therapeutics Co LtdSolid tumours
Details
PMI-06PMI06; PMI-06Phase 1 ClinicalPrecision Molecular IncCarcinoma, Non-Small-Cell Lung
Details
A-337 (Klus Pharma)A337 (Klus Pharma); A-337 (Klus Pharma)Phase 1 ClinicalKlus Pharma IncNeoplasms
Details
LW-347LW-347Phase 1 ClinicalShanghai Longwood Biopharmaceuticals Co LtdNeoplasms
Details
BHP-01BHP-01; BHP01; α-PD-L1/4-1BB DLL3 CAR-TPhase 1 ClinicalChengdu Brilliant Pharmaceutical Co LtdSmall Cell Lung Carcinoma
Details
CVL006CVL006; B006Phase 1 ClinicalFukang (Shanghai) Health Technology Co LtdSolid tumours; Neoplasms
Details
DCR-PDL1DCR-PDL1Phase 1 ClinicalDicerna Pharmaceuticals IncSolid tumours
Details
Naptumomab estafenatox/DurvalumabNTX-352Phase 1 ClinicalNeotx Therapeutics LtdSolid tumours
Details
ReozalimabIBI-318; LY-3434172; LY3434172Phase 1 ClinicalInnovent Biologics(Suzhou) Co Ltd, Eli Lilly And CompanyNeoplasms; Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular
Details
Pd-1-pikPd-1-pikPhase 1 ClinicalHuashan Hospital Affiliated To Fudan UniversityGlioblastoma
Details
IBC-Ab002IBC-Ab002Phase 1 ClinicalImmunoBrain Checkpoint IncAlzheimer Disease
Details
CTX-8371CTX-8371Phase 1 ClinicalCompass Therapeutics LLCSolid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Hodgkin Disease; Melanoma; Carcinoma, Non-Small-Cell Lung
Details
ABL-501ABL-501Phase 1 ClinicalAbl Bio IncSolid tumours
Details
IMGS-001IMGS-001Phase 1 ClinicalThe University Of Texas MD Anderson Cancer CenterSolid tumours; Neoplasms; Triple Negative Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms
Details
Q-1801Q-1801; Q 1801Phase 1 ClinicalQiyu Biotechnology (Shanghai) Co LtdSolid tumours
Details
QL-301QL-301Phase 1 ClinicalQlsf Biotherapeutics IncNeoplasms
Details
XirestomigATG-101; ATG101; YN051Phase 1 ClinicalThe Origin Cell Technology Group Co LtdSolid tumours; Lymphoma, B-Cell; Hematologic Neoplasms; Lymphoma, Non-Hodgkin
Details
BH-3120BH-3120Phase 1 ClinicalHanmi Pharmaceutical Co LtdSolid tumours
Details
TS-1905TS-1905; LY-01019; BA-1201Phase 1 ClinicalShandong Boan Biotechnology Co LtdSolid tumours
Details
CYTO-102CYTO-NK-102; CYTO-102; COH06Phase 1 ClinicalCytoImmune Therapeutics IncLung Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
EMB-09EMB-09Phase 1 ClinicalShanghai Epimab Biotherapeutics, IncOvarian Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Hepatitis B, Chronic; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular
Details
LP-008LP-008Phase 1 ClinicalLepu Biopharma Co LtdSolid tumours
Details
SIM-0237SIM-0237; SIM-237Phase 1 ClinicalSimcere Pharmaceutical Group LtdSolid tumours; Urinary Bladder Neoplasms
Details
AB-101 (Arbutus Biopharma)AB-101 (Arbutus Biopharma)Phase 1 ClinicalArbutus Biopharma CorpHepatitis B, Chronic; Hepatitis B
Details
anti-PSMA/anti-PSCA CAR T-cell therapy PD-1 silent (Shanghai Unicar-Therapy Bio-medicine)Phase 1 ClinicalShanghai Unicar-Therapy Bio-Medicine Technology Co LtdHormone-Resistant Prostate Neoplasms
Details
anti-PD-L1 CSR T-cell therapy (Marino Biotechnology)Phase 1 ClinicalBeijing Marino Biotechnology Co LtdGlioblastoma; Neoplasms
Details
dual anti-HER2/anti-PD-L1 CAR T-cell therapy (Sichuan University)Phase 1 ClinicalSichuan UniversityOvarian Neoplasms; Stomach Neoplasms; Peritoneal Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung
Details
SimridarlimabIBI-322; IBI322Phase 1 ClinicalInnovent Biologics(Suzhou) Co LtdHematologic Neoplasms; Bone Marrow Neoplasms; Solid tumours; Neoplasms; Lymphoma, T-Cell; Lymphoma; Leukemia, Myeloid, Acute
Details
BetifisolimabMSB-2311Phase 1 ClinicalMabspace Biomedicine (Suzhou) Co LtdSolid tumours
Details
IMMH-010IMMH-010Phase 1 ClinicalTianjin Chase Sun Pharmaceutical Co LtdSolid tumours; Neoplasms
Details
OpucolimabHLX-20Phase 1 ClinicalShanghai Henlius Biotech IncSolid tumours; Neoplasms
Details
INCB-086550INCB-086550; INCB-86550Phase 1 ClinicalIncyte CorpSolid tumours; Carcinoma; Carcinoma, Renal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma
Details
MCLA-145MCLA-145Phase 1 ClinicalIncyte Corp, Merus NvSolid tumours; Lymphoma, B-Cell; Neoplasms
Details
LOR-S03CDX-527Phase 1 ClinicalCelldex TherapeuticsOvarian Neoplasms; Liver Neoplasms; Solid tumours; Head and Neck Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
SL-279252TAK-252; SL-279252Phase 1 ClinicalShattuck Labs Inc, Takeda Pharmaceutical Co LtdSolid tumours; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Carcinoma, Transitional Cell; Carcinoma, Basosquamous; Astrocytoma; Carcinoma, Squamous Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma
Details
LodapolimabLY-3300054Phase 1 ClinicalEli Lilly And CompanySolid tumours; Skin Melanoma; Carcinoma, Renal Cell; Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech)Z-CTLsPhase 1 ClinicalHunan Zhaotai Yongren Biotech Co LtdCarcinoma, Non-Small-Cell Lung
Details
89Zr-DFO-Atezolizumab89Zr-DFO-AtezolizumabPhase 1 ClinicalThe University Of Texas Southwestern Medical CenterCarcinoma, Renal Cell; Diagnostic agents
Details
EmdifenPhase 1 ClinicalTianjin Chase Sun Pharmaceutical Co Ltd, Chinese Academy Of Medical SciencesSolid tumours
Details
LesabelimabBC-003Phase 2 ClinicalGuilin Sanjin Pharmaceutical Co Ltd, Adagene (Suzhou) Ltd, Dragonboat Biopharmaceutical, Baifan Biotechnology (Shanghai) Co LtdCarcinoma, Renal Cell; Neoplasms; Urinary Bladder Neoplasms; Penile Neoplasms
Details
ABSK-043ABSK043Phase 2 ClinicalABbisko Therapeutics Co LtdSolid tumours; Esophageal Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung
Details
PM-8003PM8003Phase 2 ClinicalSolid tumours
Details
PM-1003PM1003Phase 2 ClinicalSolid tumours
Details
IMM-2510IMM-2510; SYN-2510Phase 2 ClinicalImmuneOnco Biopharmaceuticals (Shanghai) Co LtdSolid tumours; Neoplasms; Triple Negative Breast Neoplasms; Sarcoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular
Details
PD-L1 antibody combined with CTLA-4 antibody (Shanghai Zhongshan Hospital)Phase 2 ClinicalShanghai Zhongshan HospitalCholangiocarcinoma
Details
Sotiburafusp alfaHB0025; HB-0025Phase 2 ClinicalHuaBo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co LtdSolid tumours; Hematologic Neoplasms; Kidney Neoplasms; Carcinoma, Renal Cell; Endometrial Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung
Details
HLX-301HLX-301Phase 2 ClinicalShanghai Henlius Biologics Co LtdSolid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis
Details
Q-1802Q-1802Phase 2 ClinicalQiyu Biotechnology (Shanghai) Co LtdSolid tumours; Esophageal Neoplasms; Gastrointestinal Neoplasms
Details
ADG-104ADG-104; ADG104Phase 2 ClinicalGuilin Sanjin Pharmaceutical Co Ltd, Adagene IncNeoplasms
Details
6MW-32116MW3211; 6MW-3211Phase 2 ClinicalMabwell (Shanghai) Bioscience Co LtdCarcinoma, Renal Cell; Myelodysplastic Syndromes; Neoplasms; Lymphoma; Leukemia, Myeloid, Acute; Lung Neoplasms
Details
Recombinant anti-PD-L1/TGF-β bispecific antibodyY101D; Y-101DPhase 2 ClinicalWuhan Yzy Biopharma Co LtdSolid tumours; Pancreatic Neoplasms; Carcinoma, Hepatocellular
Details
CarrizumabPhase 2 ClinicalJiangsu Hengrui Medicine Co LtdEsophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma
Details
NebratamigGNC-035Phase 2 ClinicalSichuan Baili Pharmaceutical Co LtdSolid tumours; Hematologic Neoplasms; Breast Neoplasms; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Leukemia, Lymphocytic, Chronic, B-Cell
Details
FH-2001FH-2001Phase 2 ClinicalShanghai Fosun Pharmaceutical Industrial Development Co LtdSolid tumours
Details
INCB-099280INCB-099280; INCB-99280Phase 2 ClinicalIncyte Corp LtdSolid tumours; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Mismatch Repair Deficient Cancer; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Neoplasms; Microsatellite instability-high cancer; Mesothelioma; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Melanoma
Details
QLF31907QLF31907; QLF-31907Phase 2 ClinicalQilu Pharmaceutical Co LtdSolid tumours; Neoplasms; Carcinoma, Transitional Cell; Lymphoma, Non-Hodgkin; Melanoma
Details
IBC-0966IBC-0966Phase 2 ClinicalSunHo (China) BioPharmaceutical Co LtdNeoplasms
Details
LBL-024LBL024; LBL-024Phase 2 ClinicalNanjing WeiLibo biological Technology Co LtdSolid tumours; Neoplasms; Carcinoma, Neuroendocrine
Details
BAT-7104BAT-7104Phase 2 ClinicalBio-Thera Solutions LtdSolid tumours; Neoplasms
Details
BCD-106BCD-106Phase 2 ClinicalBIOCAD JSCSolid tumours
Details
PM-1022PM-1022Phase 2 ClinicalNeoplasms
Details
HB-0028HB-0028Phase 2 ClinicalHuaBo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co LtdSolid tumours; Uterine Cervical Neoplasms
Details
99mTc-NM-0199mTc-NM-01Phase 2 ClinicalNanomab Technology LtdCarcinoma, Non-Small-Cell Lung
Details
EmfizatamabGNC-038Phase 2 ClinicalSichuan Baili Pharmaceutical Co Ltd, SystImmuneSolid tumours; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Lupus Erythematosus, Systemic; Lymphoma, Extranodal NK-T-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Central Nervous System Lymphoma
Details
LB-1410LB-1410Phase 2 ClinicalL&L Biopharma Co LtdSolid tumours; Neoplasms; Lymphoma
Details
sirpiglenastatDRP-104Phase 2 ClinicalDracen Pharmaceuticals IncSolid tumours; Fibrolamellar hepatocellular carcinoma; Carcinoma, Non-Small-Cell Lung
Details
AP-505AP-505; B1962; AP505Phase 2 ClinicalAP Biosciences IncSolid tumours; Liver Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Lung Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular
Details
18F-BMS-98622918F-BMS-986229; [18F]BMS-986229Phase 2 ClinicalBristol-Myers Squibb International Corp, PeptiDream IncEsophageal Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma
Details
6MW-35116MW-3511Phase 2 ClinicalMabwell (Shanghai) Bioscience Co LtdSolid tumours; Neoplasms
Details
AB-001 (Agastiya Biotech)AB001 (Agastiya Biotech); AB-01 (Agastiya Biotech); AB01 (Agastiya Biotech)Phase 2 ClinicalAgastiya Biotech LLCNeoplasms
Details
LB-101 (Centessa Pharmaceuticals)LB-101 (Centessa Pharmaceuticals); LB-101 Tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibodyPhase 2 ClinicalCentessa Pharmaceuticals PlcSolid tumours
Details
BPB-101BPB-101Phase 2 ClinicalBetta Pharmaceuticals Co LtdSolid tumours
Details
PacmilimabCX-072Phase 2 ClinicalCytomx Therapeutics IncSolid tumours; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Lymphoma; Melanoma
Details
PRS-344PRS-344S095012; S-095012; S-95012; PRS-344/ONC0055; PRS-344; PRS-344/S095012Phase 2 ClinicalPieris Pharmaceuticals IncSolid tumours
Details
MAX-80391MAX-80391; MAX-8Phase 2 ClinicalBeijing Re Ji Medical Technology Co LtdSolid tumours
Details
JSKN-033JSKN033; JSKN-033; JSKN-003/EnvafolimabPhase 2 ClinicalJiangsu Alphamab Biopharmaceuticals Co LtdSolid tumours; Neoplasms
Details
IO-120/ IO-103 (IO Biotech)IO-120/IO-103; IO-120+IO-103Phase 2 ClinicalIo Biotech IncLeukemia, Lymphocytic, Chronic, B-Cell
Details
DB-1419DB-1419Phase 2 ClinicalDuality Biologics (Suzhou) Co LtdSolid tumours
Details
HB-0036HB-0036Phase 2 ClinicalHuaBo Biopharm Co LtdSolid tumours; Carcinoma, Non-Small-Cell Lung
Details
AP-203AP-203; AP203Phase 2 ClinicalAP Biosciences IncSolid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung
Details
HLX-43HLX-43; HLX43Phase 2 ClinicalShanghai Henlius Biotech IncSolid tumours; Liver Neoplasms; Head and Neck Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Nasopharyngeal Carcinoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular
Details
Recombinant humanized PD-L1 monoclonal antibody (Taizhou Houde Aoke Technology)LP-002Phase 2 ClinicalTaizhou Houde Aoke Technology Co LtdSolid tumours; Lymphoma, B-Cell; Small Cell Lung Carcinoma; Digestive System Neoplasms; Primary mediastinal B cell lymphoma; Carcinoma, Squamous Cell; Melanoma
Details
DanburstotugSTI-3031; STI-A1015; IMC-001Phase 2 ClinicalSorrento Therapeutics IncLymphoma, T-Cell, Peripheral; Biliary Tract Neoplasms; Solid tumours; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Lymphoma, Extranodal NK-T-Cell; Lymphoma; Neoplasm Metastasis
Details
89Zr-durvalumabPhase 2 ClinicalRadboud University NijmegenHead and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
EvixapodlinGS-4224; OX-4224Phase 2 ClinicalGilead Sciences IncSolid tumours; Carcinoma, Non-Small-Cell Lung
Details
PM-80016MW3111; PM-8001Phase 2 ClinicalSolid tumours; Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital)Phase 2 ClinicalChanghai Hospital Of ShanghaiPancreatic Neoplasms
Details
BMS-936559MDX-1105; BMS-936559Phase 2 ClinicalBristol-Myers Squibb CompanyLeukemia, Myelogenous, Chronic; HIV Infections; Shock, Septic; Hodgkin Disease; Small Cell Lung Carcinoma; Neoplasms; Sepsis; Multiple Myeloma; Lymphoma, Non-Hodgkin; Melanoma
Details
RG-6084RG-6084; RO-7191863Phase 2 ClinicalF. Hoffmann-La Roche LtdHepatitis B, Chronic; Hepatitis B
Details
VudalimabXmAb-717; XmAb-20717; XmAb 717Phase 2 ClinicalXencor IncFallopian Tube Neoplasms; Breast Neoplasms; Vulvar Neoplasms; Nasopharyngeal Carcinoma; Adenocarcinoma, Clear Cell; Prostatic Neoplasms; Astrocytoma; Colorectal Neoplasms; Carcinoma, Neuroendocrine; Endometrial Neoplasms; Cholangiocarcinoma; Thymoma; Carcinoma, Squamous Cell; Castration-Sensitive Prostate Neoplasms; Thyroid Neoplasms; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Ovarian Neoplasms; Solid tumours; Rectal Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Esophageal Neoplasms; Stomach Neoplasms; Small Cell Lung Carcinoma; Biliary Tract Neoplasms; Colonic Neoplasms; Adenoma, Acidophil; Carcinoma, Ovarian Epithelial; Hodgkin Disease; Mesothelioma; Microsatellite instability-high cancer; Adnexal Diseases; Prostatic Neoplasms, Castration-Resistant
Details
Durvalumab/GefitinibPhase 2 ClinicalMedimmuneCarcinoma, Non-Small-Cell Lung
Details
RC-98RC-98; RC98; RC98-ADCPhase 2 ClinicalRemeGen Co LtdSolid tumours; Stomach Neoplasms
Details
PD-L1 t-haNK cell therapyPhase 2 ClinicalNantkwest IncSolid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Glioblastoma; Pancreatic Neoplasms; Neoplasm Metastasis
Details
MAX-10181MAX-10181; MAX-1Phase 2 ClinicalBeijing Re Ji Medical Technology Co LtdSolid tumours; Neoplasms; Glioma
Details
FAZ-053FAZ-053; LAE-005; LAE005Phase 2 ClinicalNovartis Pharma AgSolid tumours; Triple Negative Breast Neoplasms; Chordoma; Sarcoma, Alveolar Soft Part
Details
PM-8002PM8002; PM-8002; BNT-327Phase 3 ClinicalBiotheus IncSolid tumours; Liver Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Triple Negative Breast Neoplasms; Neuroendocrine Tumors; Mesothelioma; Breast Neoplasms; Metastatic breast cancer; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular
Details
HL-301HL-301Phase 3 ClinicalHanmi Pharmaceutical Co LtdRadiation Pneumonitis; Acute Bronchitis; Pulmonary Disease, Chronic Obstructive; Lung Neoplasms
Details
AcasunlimabPD-L1x4-1BB; DuoBody-PD-L1x4-1BB; GEN1046; BNT-311Phase 3 ClinicalGenmab A/S, Biontech SeSolid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms
Details
ErfonrilimabKN-046; KN046; KNO-46Phase 3 ClinicalJiangsu Alphamab Biopharmaceuticals Co LtdColorectal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Lymphoma; Thymoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Pancreatic Ductal; Thymus Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Colonic Neoplasms; Triple Negative Breast Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Solid tumours
Details
Bintrafusp alfaM-7824; GSK-4045154; MSB-0011359CPhase 3 ClinicalMerck SeronoBrain metastases; Cholangiocarcinoma; Breast Neoplasms; Microsatellite Instability; Vulvar Neoplasms; Sarcoma; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Colorectal Neoplasms; Thymus Neoplasms; Oropharyngeal Neoplasms; Gallbladder Neoplasms; Lung Neoplasms; Prostatic Neoplasms, Castration-Resistant; Lymphoma; Penile Neoplasms; Thymoma; Urogenital Neoplasms; Metastatic breast cancer; Carcinoma, Small Cell; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Neoplasm Metastasis; Sarcoma, Kaposi; Neoplasms, Germ Cell and Embryonal; Stomach Neoplasms; Solid tumours; Hematologic Neoplasms; Head and Neck Neoplasms; Intestinal Neoplasms; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Vaginal Neoplasms; Carcinoma; Carcinoma, Renal Cell; Esthesioneuroblastoma, Olfactory; Anus Neoplasms; Biliary Tract Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Nose Neoplasms; Ganglioglioma; Papillomavirus Infections; Carcinoma, Trans
Details
PD-1 Inhibitor Therapy(Hunan Cancer Hospital)Hunan Cancer Hospital
Details
TreprilimabClinicalSun Yat-Sen UniversityOropharyngeal Neoplasms
Details
INSIX RA (Indus Biotech)ClinicalIndus Biotech Pvt LtdArthritis, Rheumatoid; Inflammation
Details
64Cu-DOTA-nivolumab (Bristol-Myers Squibb/Ono Pharmaceutical)ClinicalOno Pharmaceutical Co Ltd, Bristol-Myers Squibb CompanyMelanoma; Carcinoma, Non-Small-Cell Lung
Details
Rituximab/PaclitaxelAR-160Phase 1 ClinicalMayo ClinicLymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell
Details
PD-1 knockout engineered T cells (Anhui Kedgene Biotechnology)Phase 1 ClinicalAnhui Korton Biological Technology Co LtdEsophageal Neoplasms; Carcinoma, Hepatocellular
Details
STW204STW-204; AI025; AI-025Phase 1 ClinicalSuzhou Stainwei Biotech IncSolid tumours; Neoplasms
Details
MW-11MW-11; 9MW1111; 9-MW1111; 9MW-1111; 9-MW-1111Phase 1 ClinicalMabwell (Shanghai) Bioscience Co LtdSolid tumours; Breast Neoplasms
Details
Recombinant humanized anti-PD-1 monoclonal antibody (Shanxi Wichida Bright Pharmaceutical)Phase 1 ClinicalShanxi Weiqidaguangming Pharmaceutical Co LtdSolid tumours
Details
αPD1-MSLN-CAR T cell therapy (Shanghai Cell Therapy Group Co.,Ltd)BZDS1901; BZDS-1901; BZD1901Phase 1 ClinicalShanghai Cell Therapy Group Co LtdOvarian Neoplasms; Solid tumours; Mesothelioma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
VT1093VT1093; VT-1093Phase 1 ClinicalBeijing Weiyuan Likang Biotechnology Co LtdSolid tumours
Details
NWY-001(Biocytogen Pharmaceuticals)NWY001(Biocytogen Pharmaceuticals); YH008; YH-008; NWY-001(Biocytogen Pharmaceuticals)Phase 1 ClinicalEucure Pharmaceutical Technology (Beijing) Co Ltd, Biocytogen Pharmaceuticals (Beijing) Co LtdSolid tumours; Hematologic Neoplasms; Neoplasms
Details
IBI-319IBI-319Phase 1 ClinicalInnovent Biologics(Suzhou) Co LtdNeoplasms
Details
GNR-051GNR-051Phase 1 ClinicalGenerium PharmaceuticalsCarcinoma, Renal Cell; Melanoma; Carcinoma, Non-Small-Cell Lung
Details
JS-201JS-201Phase 1 ClinicalShanghai Junshi Biosciences Co LtdNeoplasms
Details
PH762-TMERXI 762-ACT; mPH-762; PH-762; PH762-ACTPhase 1 ClinicalPhio Pharmaceuticals CorpSkin Melanoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Merkel Cell; Breast Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Lung Neoplasms; Carcinoma, Squamous Cell; Melanoma
Details
IBI-321IBI-321Phase 1 ClinicalInnovent Biologics(Suzhou) Co LtdSolid tumours; Neoplasms
Details
CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine)Phase 1 ClinicalSecond Affiliated Hospital Of Zhejiang University School Of MedicineLymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Primary mediastinal B cell lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Follicular
Details
Anti-PD1/anti-TIM3 bispecific antibody (L&L vision biopharmaceuticals)Bis-5Phase 1 ClinicalL&L Biopharma Co LtdSolid tumours; Neoplasms
Details
SSGJ-705705; SSGJ-705Phase 1 ClinicalSunshine GuoJian Pharmaceutical (Shanghai) Co LtdSolid tumours; Neoplasms
Details
SHR-1901SHR-1901Phase 1 ClinicalSuzhou Suncadia Biopharmaceuticals Co LtdNeoplasms
Details
CA-170CA-170; AUPM-170Phase 1 ClinicalAurigeneSolid tumours
Details
Recombinant human anti-PD-1 monoclonal antibody(Hec Biological)Phase 1 ClinicalDongguan City Hec Biological Medicine Res And Development Co LtdStomach Neoplasms; Esophageal adenocarcinoma
Details
LatikafuspAMG-256Phase 1 ClinicalAmgen IncSolid tumours
Details
706-3SBioSSGJ-706; 706 anti -PD1/PD -L1 BsAb; 706 anti-PD1/PD-L1 Bispecific antibodyPhase 1 Clinical3sbio IncSolid tumours; Composite Lymphoma; Neoplasms; Lymphoma
Details
89Zr-N-sucDf-pembrolizumabPhase 1 ClinicalMerck & Co Inc, Umcg The University Medical Center GroningenMelanoma; Carcinoma, Non-Small-Cell Lung
Details
AK-131AK-131Phase 1 ClinicalZhongshan Akeso Biopharma Co LtdSolid tumours; Neoplasms
Details
CDX-585CDX-585; BSI-585Phase 1 ClinicalBoaoxin Biotechnology(Nanjing) Co Ltd, Celldex TherapeuticsSolid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
ABBV-1882ABBV-1882Phase 1 ClinicalAbbvie IncHIV Infections
Details
Pegylated recombinant human granulocyte colony stimulating factor(Sun Yat-sen University)Phase 1 ClinicalSun Yat-Sen UniversityHematologic Neoplasms; Nasopharyngeal Carcinoma
Details
SOT-201SOT-201; SO C108; SO-C108Phase 1 ClinicalSotioSolid tumours; Neoplasms
Details
Sym-024Sym-024; S-95024Phase 1 ClinicalSymphogen A/SSolid tumours; Neoplasm Metastasis
Details
KY-0118KY-0118; KY0118Phase 1 ClinicalNovatim Immune Therapeutics (Zhejiang) Co LtdSolid tumours; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung
Details
JNJ-67484703JNJ-67484703; JNJ-4703Phase 1 ClinicalJanssen Research & Development LlcArthritis, Rheumatoid
Details
BC008-1ABC008-1APhase 1 ClinicalSichuan Luzhou Buchang Biopharmaceutical Co LtdSolid tumours; Esophageal Neoplasms; Glioblastoma; Glioma; Carcinoma, Non-Small-Cell Lung
Details
TC-N201(TCRCure)TC-N201Phase 1 ClinicalTcrcure Biopharma LtdSolid tumours
Details
WTX-212WTX-212Phase 1 ClinicalWestlake TherapeuticsSolid tumours; Hematologic Neoplasms; Neoplasms; Lung Neoplasms
Details
SV-102SV-102; SV102; SYNC-T SV-102Phase 1 ClinicalSyncromune IncProstatic Neoplasms, Castration-Resistant
Details
INCA33890INCA33890; INCA-33890Phase 1 ClinicalIncyte CorpSolid tumours
Details
STW204/GotistobartAI-061Phase 1 ClinicalOncoc4 IncColorectal Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Endometrial Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Ovarian Neoplasms; Urinary Bladder Neoplasms; Squamous Cell Carcinoma of Head and Neck; Cystadenocarcinoma, Serous; Carcinoma, Renal Cell; Stomach Neoplasms; Anus Neoplasms; Esophageal Neoplasms
Details
WTX-212AWTX-212A; WTX212APhase 1 ClinicalZhejiang UniversitySolid tumours
Details
HC-010(Shanghai Hongcheng)HC-010; HC010Phase 1 ClinicalShanghai Hongcheng Pharmaceutical Co LtdSolid tumours
Details
BPT-567BPT-567Phase 1 ClinicalBright Peak Therapeutics IncSolid tumours; Neoplasms
Details
PD 1-proIL-2v (Proviva Therapeutics)PTX-912Phase 1 ClinicalProviva Therapeutics IncSolid tumours; Neoplasms; Neoplasm Metastasis
Details
BZE-2209BZE-2209; BZE2209; αPD1/CTLA4-MSLN-CAR T CellsPhase 1 ClinicalShanghai Cell Therapy Group Co LtdSolid tumours
Details
BZT-2312BZT-2312; Fast CAR T cellsPhase 1 ClinicalShanghai Cell Therapy Group Co LtdSolid tumours
Details
CS-2009CS-2009Phase 1 ClinicalCstone PharmaceuticalsSolid tumours; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung
Details
CD-001CD-001Phase 1 ClinicalCD (Suzhou) Biopharma Co LtdSolid tumours; Hematologic Neoplasms; Neoplasms
Details
γδ T-PD-1 Ab Cells therapy(Changzhou No.2 People’S Hospital)Phase 1 ClinicalChangzhou No.2 People’S HospitalSolid tumours
Details
TQB-2252TQB-2252; TQB2252Phase 1 ClinicalChia Tai Tianqing (Guangzhou) Pharmaceutical Co LtdSolid tumours; Neoplasms
Details
MAQ-001MAQ-001Phase 1 ClinicalMabQuest SASolid tumours
Details
FP-008 (Fapon Biotech)FP-008; FP008Phase 1 ClinicalFapon Biotech IncNeoplasms
Details
GenSci-120GenSci-120; GenSci120Phase 1 ClinicalChangchun GeneScience Pharmaceuticals Co LtdInflammatory Bowel Diseases; Arthritis, Rheumatoid; Sjogren's Syndrome; Autoimmune Diseases; Graft vs Host Disease; Lupus Erythematosus, Systemic
Details
JMT-108JMT108; JMT-108Phase 1 ClinicalShanghai Jmt-Bio IncNeoplasms
Details
TEV-278TEV-278; TEV-‘278Phase 1 ClinicalTeva Pharmaceutical Industries LtdNeoplasms
Details
ONO-4915ONO-4915Phase 1 ClinicalOno Pharmaceutical Co LtdAutoimmune Diseases
Details
ReozalimabIBI-318; LY-3434172; LY3434172Phase 1 ClinicalInnovent Biologics(Suzhou) Co Ltd, Eli Lilly And CompanyNeoplasms; Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular
Details
CTX-8371CTX-8371Phase 1 ClinicalCompass Therapeutics LLCSolid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Hodgkin Disease; Melanoma; Carcinoma, Non-Small-Cell Lung
Details
MVR-C5252C-5252; MVR-C5252; T-5Phase 1 ClinicalImmvira Co LtdSolid tumours; Ganglioglioma; Glioblastoma; Brain Neoplasms; Glioma
Details
ASKG-915ASKG-915Phase 1 ClinicalAskgene PharmaSolid tumours; Neoplasms
Details
Mableukin 2PD1 (Anwita Biosciences)AWT020; AWT-020Phase 1 ClinicalAnwita Biosciences IncSolid tumours; Carcinoma, Renal Cell; Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Autoimmune Diseases of the Nervous System
Details
GS-0151GS-0151; MB-151Phase 1 ClinicalUniversity Of OxfordAutoimmune Diseases; Inflammation
Details
iCasp9M28z T cellsPhase 1 ClinicalMemorial Sloan Kettering Cancer CenterMesothelioma; Breast Neoplasms; Lung Neoplasms
Details
rHSV-1-APD1YST-02Phase 1 ClinicalXiamen UniversitySolid tumours; Neoplasms; Central Nervous System Neoplasms; Glioma
Details
MHC-001MHC-001Phase 1 ClinicalSichuan UniversityCarcinoma, Non-Small-Cell Lung
Details
Sofusa anti-PD-1Phase 1 ClinicalSorrento Therapeutics IncLymphoma, T-Cell, Cutaneous
Details
Yinkang-001Phase 1 ClinicalSolid tumours
Details
TaminadenantNIR-178; PBF-509Phase 1 ClinicalPalobiofarma SlHead and Neck Neoplasms; Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Carcinoma; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Prostatic Neoplasms, Castration-Resistant; Colorectal Neoplasms; Parkinson Disease; Carcinoma, Pancreatic Ductal; Melanoma; Carcinoma, Non-Small-Cell Lung
Details
Nivolumab biosimilar (Mabpharm)CMAB8-19; CMAB-819Phase 1 ClinicalSinomab Bioscience LtdSquamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular
Details
RB-0004RB-0004Phase 1 ClinicalReyoung Pharmaceutical Co LtdSolid tumours; Lymphoma
Details
ONO-4685ONO-4685Phase 1 ClinicalMerus NvLymphoma, T-Cell; Plaque psoriasis; Leukemia, Lymphocytic, Chronic, B-Cell
Details
Sym-021Sym-021; S-95016; Sym021Phase 1 ClinicalSymphogen A/SSolid tumours; Lymphoma; Neoplasm Metastasis
Details
IzuralimabXmAb-23104; XmAb-104Phase 1 ClinicalXencor IncTriple Negative Breast Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Endometrial Neoplasms; Colorectal Neoplasms; Sarcoma; Nasopharyngeal Carcinoma; Solid tumours; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell
Details
EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania)LXF-821Phase 1 ClinicalUniversity Of Pennsylvania, Novartis Pharma AgGlioblastoma
Details
Eciskafusp AlfaRO-7284755; RG-6279; PD1-IL2vPhase 1 ClinicalF. Hoffmann-La Roche AgSolid tumours; Urinary Bladder Neoplasms
Details
CC-90006C-90006; CC-90006Phase 1 ClinicalAnaptysbio IncAutoimmune Diseases; Psoriasis
Details
ZeluvalimabAMG-404Phase 1 ClinicalAmgen IncSolid tumours; Small Cell Lung Carcinoma; Prostatic Neoplasms, Castration-Resistant; Precursor Cell Lymphoblastic Leukemia-Lymphoma
Details
FidasimtamabIBI-315; BH-2950Phase 1 ClinicalHanmi Pharmaceutical Co Ltd, Innovent Biologics(Suzhou) Co LtdSolid tumours; Neoplasms
Details
SYN-125SYN-125Phase 1 ClinicalSynermore Biologics (Suzhou) Co LtdSolid tumours; Carcinoma
Details
Multiple target antigen stimulating cell therapy (HengRui YuanZheng Biotechnology)Phase 1 ClinicalHengrui Yuanzheng (Shanghai) Biotechnology Co LtdSolid tumours; Liver Neoplasms; Stomach Neoplasms; Liver Diseases
Details
GX-P1GX-P1; PD-L1 hyfcPhase 1 ClinicalGenexine IncAutoimmune Diseases; Rejection of organ transplantation
Details
Recombinant human PD-1 antibody herpes simplex virusPhase 1 ClinicalYangsheng Tang Co Ltd, Xiamen UniversityHead and Neck Neoplasms; Solid tumours; Liver Neoplasms; Pancreatic Neoplasms; Neoplasms; Central Nervous System Neoplasms; Urinary Bladder Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Brain metastases; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Hepatocellular
Details
HX-009HX-009; HX009-II-02Phase 2 ClinicalWaterstone Hanxbio Pty LtdSolid tumours; Liver Neoplasms; Biliary Tract Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Bile Duct Neoplasms; Lymphoma; Melanoma
Details
PD-1 knockout engineered T cells (Chengdu MedGenCell)Phase 2 ClinicalWest China Hospital Of Sichuan University, Chengdu MedgencellLung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma
Details
LipustobartLZM-009Phase 2 ClinicalLivzon(Group) Pharmaceutical FactorySolid tumours; Thymoma; Carcinoma, Non-Small-Cell Lung
Details
AcrixolimabYBL-006; YBL 006Phase 2 ClinicalY-biologics IncSolid tumours
Details
RC-148RC-148Phase 2 ClinicalRemeGen Co LtdSolid tumours; Breast Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung
Details
EMB-02EMB-02Phase 2 ClinicalShanghai Epimab Biotherapeutics, IncSolid tumours
Details
IMU-201IMU-201; APi-2568; KEY-Vaxx; PD1-VaxxPhase 2 ClinicalImugene LtdAdenocarcinoma of Lung; Carcinoma, Large Cell; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
LBL-015LBL-015Phase 2 ClinicalNanjing WeiLibo biological Technology Co LtdSolid tumours; Neoplasms
Details
PradusinstobartLVGN-3616; SSI-361Phase 2 ClinicalLyvgen Biopharma(HK)LtdSolid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Papillomavirus Infections; Uveal melanoma; Sarcoma; Carcinoma, Hepatocellular; Neoplasm Metastasis
Details
PidilizumabMDV-9300; CT-011Phase 2 ClinicalCuretech LtdLymphoma, B-Cell, Marginal Zone; Ovarian Neoplasms; Carcinoma, Renal Cell; Lymphoma, Large B-Cell, Diffuse; Colonic Neoplasms; Pancreatic Neoplasms; Multiple Myeloma; Primary mediastinal B cell lymphoma; Sarcoma; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Lymphoma; Melanoma; Carcinoma, Hepatocellular; Hepatitis C, Chronic
Details
TQB-2868TQB-2868Phase 2 ClinicalNeoplasms; Pancreatic Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms
Details
RosnilimabANB-030Phase 2 ClinicalAnaptysbio IncAlopecia Areata; Arthritis, Rheumatoid; Colitis, Ulcerative
Details
IAP-0971IAP-0971Phase 2 ClinicalSunHo (China) BioPharmaceutical Co LtdSolid tumours; Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
AK-129AK-129Phase 2 ClinicalZhongshan Akeso Biopharma Co LtdSolid tumours; Esophageal Neoplasms; Stomach Neoplasms; Hodgkin Disease; Neoplasms; Adenocarcinoma
Details
HerinCAR-PD1Phase 2 ClinicalNingbo Cancer HospitalSolid tumours
Details
Anti-CTLA-4/PD-1 expressing EGFR-CAR-TPhase 2 ClinicalShanghai Cell Therapy Research InstituteSolid tumours
Details
EBV-specific TCR-T cell with anti-PD1 auto-secreted elementPhase 2 ClinicalTcrcure Biopharma LtdSquamous Cell Carcinoma of Head and Neck
Details
707 (3SBio)SSGJ-707; SSGJ707; 707Phase 2 Clinical3sbio IncSolid tumours; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
IBI-363IBI-363Phase 2 ClinicalInnovent Biologics(Suzhou) Co LtdSolid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Mucosal Melanoma; Neoplasms; Colorectal Neoplasms; Lymphoma; Melanoma; Carcinoma, Non-Small-Cell Lung
Details
PeramprizumabPhase 2 ClinicalSun Yat-Sen UniversityNasopharyngeal Carcinoma
Details
SAR-445877SAR445877; SAR-445877; KD050; KD-050Phase 2 ClinicalSanofi, Kadmon Corporation LlcSolid tumours
Details
OSE-279OSE-279Phase 2 ClinicalOse ImmunotherapeuticsSolid tumours; Lymphoma
Details
PD-1 Inhibitor Therapy (Gene Key Life)Phase 2 ClinicalBeijing Gene Key Life Technology Co LtdCarcinoma, Hepatocellular
Details
PD-1 Monoclonal Antibody(Sixth Affiliated Hospital Sun Yat-Sen University)Phase 2 ClinicalSixth Affiliated Hospital Sun Yat-Sen UniversityNasopharyngeal Neoplasms; Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms
Details
Recombinant humanized anti-PD-1 monoclonal antibody (Anhui Anke Biotechnology)Phase 2 ClinicalAnhui Anke Biotechnology (Group) Co LtdEsophageal Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Lymphoma; Lung Neoplasms
Details
MHB-039-AMHB039A; MHB-039-APhase 2 ClinicalMinghui Pharmaceutical (Hangzhou) Co LtdSolid tumours; Neoplasms; Breast Neoplasms; Lung Neoplasms
Details
PD-1 inhibitor therapy(Shanghai Chest Hospital)Phase 2 ClinicalShanghai Chest HospitalEsophageal Neoplasms; Esophageal Squamous Cell Carcinoma
Details
PD-1 Inhibitor Therapy(Affiliated Hospital of Nantong University)Phase 2 ClinicalAffiliated Hospital Of Nantong UniversityEsophageal Squamous Cell Carcinoma
Details
SCTB-14SCTB14; SCTB-14Phase 2 ClinicalSinoCelltech LtdSolid tumours; Carcinoma, Non-Small-Cell Lung
Details
EzabenlimabBI-754091Phase 2 ClinicalC.H. Boehringer Sohn Ag & Co. KgSarcoma; Melanoma; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Neuroendocrine; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Solid tumours; Soft Tissue Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Colonic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Biliary Tract Neoplasms; Liver Neoplasms; Head and Neck Neoplasms
Details
Recombinant human anti-PD-1 monoclonal antibody(CSPC Zhongqi Pharma)Phase 2 ClinicalCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co LtdSolid tumours; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung
Details
Anti-PD-1 Antibody(Jiangxi Provincial Cancer Hospital)Phase 2 ClinicalJiangxi Provincial Cancer HospitalNasopharyngeal Carcinoma
Details
LM-299LM299; LM-299Phase 2 ClinicalLaNova Medicines LtdSolid tumours; Neoplasms
Details
SCTB-41SCTB41; SCTB-41; SCT-B41Phase 2 ClinicalSinoCelltech LtdSolid tumours
Details
HY-07121HY-07121; HY07121Phase 2 ClinicalSichuan Huiyu Seacross Pharma Technology LtdSolid tumours
Details
AI-081AI-081Phase 2 ClinicalOncoc4 IncSolid tumours
Details
BPT-958BPT-958; BPT958Phase 2 ClinicalBright Peak Therapeutics IncNeoplasms
Details
SabestomigAZD-7789Phase 2 ClinicalAstraZeneca AgSolid tumours; Esophageal Neoplasms; Stomach Neoplasms; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis
Details
JS-207JS-207Phase 2 ClinicalDotbio Pte LtdNeoplasms; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army)Phase 2 ClinicalPeople'S Liberation Army General Hospital Military ServiceMultiple Myeloma
Details
TY-101TY-101; TY101Phase 2 ClinicalTayu Huaxia Biotech Medical Group Co LtdSolid tumours; Lymphoma
Details
Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute)Phase 2 ClinicalShanghai Cell Therapy Research InstituteNeoplasms
Details
T-3011T-3 (ImmVira Pharma); MVR-T3011; T3011; MVR-T3011 IT; MVR-T3011 IV; B015; B-015Phase 2 ClinicalImmvira Co LtdSarcoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Endometrial Neoplasms; Lung Neoplasms; Lymphoma; Carcinoma, Squamous Cell; Colorectal Neoplasms; Breast Neoplasms; Solid tumours; Urinary Bladder Neoplasms; Mesothelioma; Ascites; Skin Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Ovarian Neoplasms; Liver Neoplasms; Head and Neck Neoplasms
Details
ZG-005ZG-005Phase 2 ClinicalGensun Biopharma IncSolid tumours; Bile Duct Neoplasms; Lymphoma; Carcinoma, Neuroendocrine; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular
Details
MiHA-loaded PD-L silenced DC vaccination (Radboud University)Phase 2 ClinicalRadboud University NijmegenHematologic Neoplasms; Colorectal Neoplasms
Details
LomvastomigRG-7769; RO-7121661; R07121661Phase 2 ClinicalF. Hoffmann-La Roche LtdSolid tumours; Small Cell Lung Carcinoma; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung
Details
PeresolimabLY-3462817Phase 2 ClinicalEli Lilly And CompanyAutoimmune Diseases; Arthritis, Rheumatoid; Connective Tissue Diseases; Joint Diseases; Immune System Diseases; Musculoskeletal Diseases; Psoriasis; Rheumatic Diseases; Arthritis
Details
PD-1 knockout EBV-CTL (Nanjing Medical University)Phase 2 ClinicalNanjing Medical UniversityStomach Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Neoplasms; Lymphoma
Details
LorigerlimabMGD-019; AEX1344Phase 2 ClinicalMacrogenics IncAdenocarcinoma, Clear Cell; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Uterine Cervical Neoplasms; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Fallopian Tube Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Hormone-Resistant Prostate Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasms; Ovarian Clear Cell Carcinoma; Carcinoma, Renal Cell; Solid tumours; Skin Melanoma
Details
Recombinant humanized anti-PD-1 monoclonal antibody (Shanghai CP Guojian)609-A; SSGJ-609A; SSGJ-609-APhase 2 ClinicalSunshine GuoJian Pharmaceutical (Shanghai) Co LtdSolid tumours; Sarcoma; Breast Neoplasms
Details
DanvilostomigSI-B003Phase 2 ClinicalSichuan Baili Pharmaceutical Co LtdSolid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis; Melanoma
Details
TobemstomigRO-7247669Phase 2 ClinicalF. Hoffmann-La Roche LtdSolid tumours; Liver Neoplasms; Carcinoma; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma
Details
MAX-10181MAX-10181; MAX-1Phase 2 ClinicalBeijing Re Ji Medical Technology Co LtdSolid tumours; Neoplasms; Glioma
Details
PimivalimabJTX-4014Phase 2 ClinicalJounce Therapeutics IncNeoplasms; Carcinoma, Non-Small-Cell Lung
Details
dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics)ICTCAR-014Phase 2 ClinicalInnovative Cellular Therapeutics Co LtdLymphoma, Non-Hodgkin
Details
PE0105PE-0105Phase 2 ClinicalShanghai Yunyi Health Technology Development Co LtdSolid tumours; Neoplasms
Details
SpartalizumabPDR-001Phase 3 ClinicalNovartis Pharma AgLung Neoplasms; Neuroendocrine Tumors; Uveal melanoma; Mesothelioma; Nasopharyngeal Carcinoma; Breast Neoplasms; Cholangiocarcinoma; Sarcoma; Prostatic Neoplasms; Colorectal Neoplasms; Bone Marrow Diseases; Gastrointestinal Stromal Tumors; Primary Myelofibrosis; Sarcoma, Alveolar Soft Part; Esophageal Squamous Cell Carcinoma; Leukemia, Myeloid, Acute; Digestive System Neoplasms; Lymphoma; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Metastatic breast cancer; Esophageal adenocarcinoma; Endometrial Neoplasms; Thyroid Neoplasms; Uterine Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Thrombocythemia, Essential; Uterine Cervical Neoplasms; Adenocarcinoma; Persistent Fetal Circulation Syndrome; Pancreatic Neoplasms; Leukemia; Kidney Neoplasms; Solid tumours; Liver Neoplasms; Preleukemia; Hematologic Diseases; Ovarian Neoplasms; Skin Melanoma; Head and Neck Neoplasms; Carcinoma, Renal Cell; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Polycythemia Vera; Anus Neopla
Details
Nivolumab biosimilar (Shandong Boan Biotechnology)LY-01015; BA-1104Phase 3 ClinicalShandong Boan Biotechnology Co LtdLiver Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Urinary Bladder Neoplasms; Mesothelioma; Glioma; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung
Details
Mavezelimab/PembrolizumabMK-4280A; MK-4820APhase 3 ClinicalMerck Sharp & Dohme CorpSolid tumours; Carcinoma, Renal Cell; Hodgkin Disease; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Colorectal Neoplasms; Carcinoma, Squamous Cell; Endometrial Neoplasms; Neoplasm Metastasis
Details
Pembrolizumab/QuavonlimabMK-1308APhase 3 ClinicalMerck Sharp & Dohme Corp, Msd Ireland (Carlow), MSD R&D(China)Co LtdSolid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Melanoma
Details
RilvegostomigAZD-2936Phase 3 ClinicalAstrazeneca PlcBiliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Cholangiocarcinoma; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular
Details
Pembrolizumab/VibostolimabMK-7684APhase 3 ClinicalMerck & Co IncCholangiocarcinoma; Uterine Cervical Neoplasms; Neoplasm Metastasis; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Gallbladder Neoplasms; Lung Neoplasms; Hematologic Neoplasms; Urinary Bladder Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Ovarian Neoplasms
Details
Hyaluronidase/PembrolizumabMK-3475APhase 3 ClinicalMerck Sharp & Dohme CorpSolid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Lung Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Melanoma
Details
Pembrolizumab biosimilar (biocad)BCD-201Phase 3 ClinicalBIOCAD JSCSkin Melanoma; Solid tumours; Carcinoma, Non-Small-Cell Lung; Melanoma
Details
Nivolumab biosimilar(Amgen)ABP-206Phase 3 ClinicalAmgen IncMelanoma
Details
Pembrolizumab biosimilar (Qilu)QL2107; QL-2107Phase 3 ClinicalQilu Pharmaceutical Co LtdEsophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma
Details
PD-1 Inhibitor Therapy(Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University)Phase 3 ClinicalSun Yat-Sen Memorial Hospital Of Sun Yat-Sen UniversitySquamous Cell Carcinoma of Head and Neck; Rejection of liver transplantation; Carcinoma, Hepatocellular
Details
BAT-3306BAT3306; BAT-3306Phase 3 ClinicalBio-Thera Solutions LtdCarcinoma, Non-Small-Cell Lung
Details
Pembrolizumab Biosimilar(Sandoz)GME-751; GME751Phase 3 ClinicalSandozCarcinoma, Non-Small-Cell Lung; Melanoma
Details
Nivolumab biosimilar (Biocad)BCD-263Phase 3 ClinicalBIOCAD JSCSkin Melanoma; Melanoma
Details
Pembrolizumab biosimilar (Shanghai Henlius Biotech Inc)HLX-17Phase 3 ClinicalShanghai Henlius Biotech IncSolid tumours; Carcinoma, Non-Small-Cell Lung
Details
Pembrolizumab Biosimilar (Samsung Bioepis )SB27; SB-27Phase 3 ClinicalSamsung Bioepis Co LtdCarcinoma, Non-Small-Cell Lung
Details
Pembrolizumab biosimilar(R-Pharm)RPH-075Phase 3 ClinicalR-PharmSkin Melanoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung
Details
Pembrolizumab biosimilar (Laboratorio Elea Phoenix Sa)MB-12; MB12Phase 3 ClinicalLaboratorio Elea Phoenix SaCarcinoma, Non-Small-Cell Lung
Details
Pembrolizumab biosimilar (Amgen)ABP 234; ABP-234Phase 3 ClinicalAmgen IncCarcinoma, Non-Small-Cell Lung
Details
Pembrolizumab biosimilar (Celltrion)CT-P51Phase 3 ClinicalCelltrion IncStomach Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma
Details
Nivolumab biosimilar(Sandoz)JPB898; JPB-898Phase 3 ClinicalSandozMelanoma
Details
Atigotatug/NivolumabBMS-986489Phase 3 ClinicalBristol-Myers Squibb CompanySmall Cell Lung Carcinoma
Details
Pembrolizumab biosimilar(Formycon)FYB-206Phase 3 ClinicalFormycon AGNeoplasms; Carcinoma, Non-Small-Cell Lung
Details
RulonilimabF-520Phase 3 ClinicalShandong New Time Pharmaceutical Co LtdLymphoma, T-Cell, Peripheral; Solid tumours; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung; Central Nervous System Lymphoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms
Details
TebotelimabPD-1 X LAG-3; MGD-013Phase 3 ClinicalMacrogenics IncNeoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Melanoma; Neoplasm Metastasis; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Endometrial Neoplasms; Cholangiocarcinoma; Small Cell Lung Carcinoma; Solid tumours; Triple Negative Breast Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Hematologic Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Biliary Tract Neoplasms; Liver Neoplasms
Details
Nurulimab/ProlgolimabBCD-217; BCD-145/BCD-100Phase 3 ClinicalBIOCAD JSCSkin Melanoma; Melanoma
Details
VolrustomigMEDI-5752; MEDI5752Phase 3 ClinicalMedimmune LlcBiliary Tract Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Mesothelioma; Sarcoma; Colorectal Neoplasms; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular
Details
GenolimzumabCBT-501; APL-501; APL501; GB226; GB-226Phase 3 ClinicalCbt, Genor Biopharma Co Ltd, Apollomics IncThymus Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Thymoma; Neoplasms, Unknown Primary; Sarcoma, Alveolar Soft Part; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, T-Cell, Peripheral; Colorectal Neoplasms; Microsatellite Instability; Hodgkin Disease; Mismatch Repair Deficient Cancer; Carcinoma, Renal Cell; Lymphoma, B-Cell; Solid tumours
Details
BAT-1308BAT-1308Phase 3 ClinicalBio-Thera Solutions LtdSolid tumours; Triple Negative Breast Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms
Details
SasanlimabRN-888; PF-06801591; PF-6801591Phase 3 ClinicalPfizer IncCarcinoma, Squamous Cell; Neoplasms, Glandular and Epithelial; Urinary Bladder Neoplasms; Urologic Diseases; Sarcoma; Prostatic Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms; Urologic Neoplasms; Carcinoma, Pancreatic Ductal; Kidney Diseases; Endometrial Neoplasms; Urogenital Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Fructose Intolerance; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Renal Cell; Ovarian Neoplasms; Head and Neck Neoplasms; Skin Melanoma; Lymphoma, T-Cell, Peripheral; Kidney Neoplasms; Carcinoma; Esophageal Neoplasms; Stomach Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse
Details
NofazinlimabCS-1003Phase 3 ClinicalCstone PharmaceuticalsSolid tumours; Neoplasms; Lymphoma; Carcinoma, Hepatocellular
Details
IparomlimabQL1604; QL-1604; PSB-103Phase 3 ClinicalQilu Pharmaceutical Co LtdSolid tumours; Liver Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Adenocarcinoma
Details
CetrelimabJNJ-63723283; JNJ-3283Phase 3 ClinicalJohnson & JohnsonSolid tumours; Hepatitis B, Chronic; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Melanoma; Carcinoma, Non-Small-Cell Lung
Details
BudigalimabABBV-181Phase 3 ClinicalAbbvie IncSolid tumours; HIV Infections; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Esophageal adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular
Details

Resource download

  • Background
  • Product Features
  • Product List
  • Validation Data
  • Clinical Drug Information Table
  • Related Product Recommendations
  • Resource download
Kontaktieren Sie uns